S. 3474, the Cannabinoid Safety and Regulation Act, brings cannabis and cannabinoid products under federal FDA oversight for the first time, establishing comprehensive safety standards, labeling requirements, manufacturing controls, and age-restriction rules for products containing THC. The bill creates a federal registration system for cannabinoid manufacturers and distributors, sets serving-size limits (primarily 5mg THC per serving), requires laboratory testing for contaminants and potency, prohibits sales to anyone under 21, and bans marketing tactics targeting minors such as candy-shaped or flavored products. It grants the FDA enforcement authority including civil penalties up to $15,000 per violation (with higher penalties for knowing violations), product recall powers, and import controls similar to those used for tobacco products. Additionally, the bill requires the Department of Transportation to study cannabis-impaired driving and funds prevention programs with $30 million annually through 2030, while preserving states' authority to impose stricter regulations except on labeling standards. The FDA must finalize most regulations within one to three years of enactment.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.